85-C00151511

[PAGE 2]
I am enclosing a copy of our quarterly report for your information. You will be chiefly interested in the materlal beginning on Page 7. 17. and 19. We are now beginntng preliminary work with the monoethylamide of Iysergic acid (lAE-32), but probably studies with this compound will not be extensive.

I have had a letter from the Sandoz company indicating that they will prepare agram of LSD-25 for \$2O0.O0and I havz ordered this material. This should be ample for any future work contemplated, Including animal neurophyslology. I might suggest that persons who are interested in this drug might write to Sandoz, since it would sezm likely the cómpany would prefer to make a larger batch of the material for sale to all-who are interested.

I have become interested in doing some preliminary experlnents with chloropromazine, a fhenothlazine derivative developed In France, but which can be obtained through Smith-Kline and French. The European clinlcal Ilteraturc states that this material is a powerful sedative drug which produces profound effects on the autonomic nervous system es well. Smith-Kline and French has alrzady promised me a supply.

! =ill attend the meeting of the Drug Addlctlon Commitlee in Boston on Novcmber óth and 7th. lf circumstances permit, l may stop in Washington durlng the following week. I cannot be sure of thé date, since It is also possible that l may have to attend a meeting in New York following the meetlng of the Drug Addictlon Committee.

Very sincerely yours, i

Harris Isbell, M.D. Director of Research

C00151511

LEXKY 477

FEDERAL SECURITY AGENCY PUBLIC HEALTH SERVICE LEXINGTON. KENTUCKY. . 26 October 1953

IN REPLYING, AOORESS THS KODIEAKOBFICZIUNCHARSE PUCLIC HEALTH SERVICE HOSPITAL NIMH Addictlon Research Center

Hi:rn Enclosure

Declasgi FEB 1977 187472 date